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X-linked intellectual disability (XLID) is a heteroge-
neous syndrome affecting mainly males. Human
genetics has identified >100 XLID genes, although
the molecular and developmental mechanisms un-
derpinning this disorder remain unclear. Here, we
employ an embryonic stem cell model to explore
developmental functions of a recently identified
XLID gene, the RNF12/RLIM E3 ubiquitin ligase. We
show that RNF12 catalytic activity is required for
proper stem cell maintenance and neural differentia-
tion, and this is disrupted by patient-associated
XLID mutation. We further demonstrate that RNF12
XLID mutations specifically impair ubiquitylation of
developmentally relevant substrates. XLID mutants
disrupt distinct RNF12 functional modules by either
inactivating the catalytic RING domain or interfering
with a distal regulatory region required for efficient
ubiquitin transfer. Our data thereby uncover a key
function for RNF12 E3 ubiquitin ligase activity in
stem cell and neural development and identify mech-
anisms by which this is disrupted in intellectual
disability.
INTRODUCTION
Intellectual disability (ID) is a genetically heterogeneous and
poorly understood developmental disorder, characterized by
limited intellectual functioning and cognitive or adaptive
behavior (van Bokhoven, 2011). It is estimated that ID affects
1%–2% of the world’s population. ID is characterized by abnor-
malities in various facets of neural development, including induc-
tion of neural differentiation genes, formation and establishment
of neural projections, dendritic arborization, and dendritic spine
morphology (Penzes et al., 2011; Telias and Ben-Yosef, 2014).
Optimal kinetic and functional parameters of neural development
are required for normal intellectual function, such that positive or
negative deviation from these thresholds can lead to ID. ForCe
This is an open access article undexample, abnormal neural specialization (Telias and Ben-Yosef,
2014) and dendritic spine arborization (Iwase et al., 2016; Korb
et al., 2017) are associated with ID syndromes. These and other
neuropathological features of XLID have been modeled in vitro
using pluripotent stem cells (Telias and Ben-Yosef, 2014).
At the molecular level, genome sequencing has identified
many genesmutated in ID, including those with functions in tran-
scription, chromatin, and cell signaling. Genes encoding en-
zymes involved in regulating post-translational modifications
(PTMs) are frequently mutated in ID and related syndromes.
These include the protein kinases DYRK1A (Luco et al., 2016),
CDK16 (Deciphering Developmental Disorders Study, 2017),
RSK2 (Delaunoy et al., 2001), and CASK (Hackett et al., 2010);
the lysine demethylase KDM5C (Gonc¸alves et al., 2014); the E2
ubiquitin-conjugating enzyme UBE2A (Tsurusaki et al., 2017);
the E3 ubiquitin ligases HUWE1 (Froyen et al., 2008), TRIP12
(Bramswig et al., 2017; Zhang et al., 2017), and MID2 (Geetha
et al., 2014); and the deubiquitylases USP7 and OTUD6B (San-
tiago-Sim et al., 2017). Mutations in cell signaling regulators
therefore represent an important class of ID, although the mech-
anisms by which disruptions in these components cause ID
remain uncertain.
The X chromosome has been identified as an important
genetic center for defining intellectual capacity. X-linked intel-
lectual disability (XLID) represents a common subtype of ID, ac-
counting for an estimated 16% of all male ID cases. Mutations in
the X-linked E3 ubiquitin ligase RNF12/RLIM were reported in
multiple XLID kindreds (Hu et al., 2016; Tønne et al., 2015),
reinforcing the key role of protein ubiquitylation in intellectual
development. RNF12 mutations are unique disease-linked X
chromosome alterations that tightly segregate with affected
males in XLID families (Hu et al., 2016; Tønne et al., 2015).
RNF12 plays a critical role in processes with potential impor-
tance for intellectual development, including X chromosome
inactivation (XCI) (Jonkers et al., 2009; Shin et al., 2010) and em-
bryonic stem cell (ESC) differentiation (Zhang et al., 2012). How-
ever, the role of RNF12 in XLID and development of the nervous
system has not been investigated.
Here, we show that RNF12/Rlimmutation in male ESCs accel-
erates induction of neural lineage markers and establishment of
neurite outgrowths, a phenotype associated with ID. RNF12 E3ll Reports 23, 1599–1611, May 8, 2018 ª 2018 The Author(s). 1599
er the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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ubiquitin ligase activity supports the stem cell state to control
ESC development, suggesting that RNF12 catalytic activity
may be relevant for XLID pathogenesis. We show that RNF12/
RLIM XLID mutants display impaired ubiquitylation of the key
developmental RNF12 substrates REX1 and SMAD7. RNF12/
RLIM XLID mutations disrupt E3 ligase activity via distinct mech-
anisms. RING domain mutants severely impair catalysis; muta-
tions in a previously unappreciated basic regulatory region also
interfere with ubiquitin transfer. Finally, we generate a knockin
ESC model to confirm that RNF12 XLID mutation disrupts sub-
strate degradation, stem cell maintenance, and neural differenti-
ation. Altogether, these results map out a pathway whereby
RNF12/RLIM mutations in XLID patients disrupt E3 ubiquitin
ligase activity, leading to abnormal stem cell behavior and accel-
erated neural development characteristic of ID.
RESULTS
RNF12/Rlim Gene Inactivation Promotes Abnormal
Neural Development from Stem Cells
Enzymes in the ubiquitin system are frequently mutated in ID,
suggesting a key role for protein ubiquitylation in neural develop-
ment and pathogenesis of intellectual disorders. RNF12/RLIM
was identified as an XLID gene, with point mutations closely
segregating with the affected males from four XLID families (Hu
et al., 2016; Tønne et al., 2015). RNF12 is implicated in aspects
of early embryonic development, including XCI (Jonkers et al.,
2009; Shin et al., 2010) and transforming growth factor b
(TGF-b)/BMP (bone morphogenic protein) signaling (Zhang
et al., 2012). We therefore hypothesized that RNF12 plays a key
role in developmental processes that may be relevant for XLID.
Previous RNF12 studies were primarily conducted in female
mice and Rlim/ ESCs, which exhibit developmental alter-
ations related to the critical role of RNF12 in XCI (Zhang et al.,
2012). However, because XLID affects mainly males, we sought
to explore how RNF12/Rlim gene inactivation in male ESCs af-
fects developmental progression of stem cells toward lineages
that make up the nervous system. Thus, we used CRISPR/
Cas9 genome editing to generate RNF12/Rlim mutant male
mouse ESCs (henceforth Rlim /y ESCs). An introduced
nonsense mutation is predicted to result in an RNF12 N-terminal
truncation, although no protein is detected (Figure S1).Figure 1. RNF12/Rlim Mutation Drives Accelerated Neural Differentiat
(A and B) Rlim +/y ESCs (black) and Rlim/y ESCs (red) were cultured in N2B27 n
relative mRNA expression of (A) Sox1, Pax6, and Ascl1 neural stem cell mark
respectively.
(C) Rlim +/y and /y ESCs were cultured in N2B27 media for 0 or 6 days and stain
used as a nuclear marker. Images were obtained as z stacks via confocal micro
derings were generated using NeuriteTracer.
(D) Quantification of average neurite outgrowth per cell (left panel) and TUJ1+ are
counted: Rlim +/y = 12,273, Rlim /y = 9,434).
(E–G) Rlim +/y and Rlim /y ESCs were subjected to LIF withdrawal for the indic
(E) NANOG, KLF4, DNMT3B, and RNF12 and ERK1/2 protein levels were determ
(F) qRT-PCR analysis of Nanog, Klf4, Fgf5, and Dnmt3b mRNA levels in Rlim +/y
(G) Rlim +/y or Rlim /y ESCs were transfected with the indicated vectors, an
determined by immunoblotting (left panel). Rlim +/y or Rlim /y ESCs were transf
were determined by immunoblotting (right panel).
Data are represented as mean ± SD (n = 3). See also Figure S1.Initially, we examined whether RNF12 is required for regulation
of differentiation toward neural lineages. We employed the
N2B27 differentiation system, which promotes efficient neural
differentiation from ESCs (Ying et al., 2003). Following transfer
into N2B27 media, Rlim +/y ESCs display a gradual increase in
expression of the neural progenitor markers Sox1 and Pax6
and the key neural stem cell factor Ascl1 (Figure 1A). Rlim /y
ESCs display a rapid increase in Sox1, Pax6, and Ascl1 expres-
sion (Figure 1A), indicating that ESC differentiation to neural lin-
eages is accelerated by RNF12/Rlim inactivation. Induction of
the mesoderm marker Brachyury/T and endoderm marker
Sox17 are diminished in Rlim /y ESCs compared to wild-type
controls (Figure 1B). Thus, RNF12 modulates ESC development
toward mesendodermal and neuroectodermal fates.
We next investigated whether the accelerated induction of
neural progenitor markers observed in differentiating Rlim /y
ESCs is accompanied by morphological hallmarks of neuronal
development. By day 6 of N2B27 differentiation, few TUJ1+ neu-
rite outgrowths are observed in Rlim +/y ESCs (Figure 1C). In
contrast, Rlim /y ESCs at day 6 frequently display an elaborate
network of TUJ1+ neurite outgrowths, in addition to TUJ1 stain-
ing in the cell body (Figure 1C). This observation is confirmed by
computational rendering to quantitatively determine the length
and area of TUJ1+ neurite outgrowths (Figure 1D). Differentiating
Rlim /y ESCs thus acquire transcriptional and morphological
characteristics of neuronal cells in advance of control Rlim +/y
ESCs. These data indicate that RNF12 controls developmental
timing during neuronal differentiation, suggesting a potential
function of RNF12 that may be disrupted in XLID.
RNF12/Rlim E3 Ligase Inactivation Leads to Loss of
Stem Cell Identity
Because RNF12 is implicated in stem cell regulation (Jonkers
et al., 2009; Shin et al., 2010; Zhang et al., 2012), we hypothe-
sized that RNF12 controls neural differentiation by regulating
expression of ESC-specific genes. We therefore investigated
the effect on RNF12/Rlim gene inactivation on expression of
the pluripotency gene regulatory network. When cultured in leu-
kemia inhibitory factor (LIF) and fetal calf serum (FCS), Rlim +/y
ESCs express high levels of key naive pluripotency factors
NANOG and KLF4, in contrast to Rlim /y ESCs (Figures 1E
and 1F). Rlim /y ESCs are more responsive to differentiationion and Aberrant ESC Pluripotency and Differentiation Signatures
eural differentiation media for the indicated time and analyzed by qRT-PCR for
ers and (B) Brachyury/T and Sox17 mesodermal and endodermal markers,
ed with TUJ1 (red) and RNF12 (green) antibodies. Hoechst staining (blue) was
scopy, and representative maximum-intensity z projections are shown. Ren-
a normalized to nuclei area (right panel) from Rlim +/y and /y ESCs (total cells
ated times.
ined by immunoblotting.
ESCs (black) and Rlim /y ESCs (red).
d NANOG, DNMT3B, KLF4, OCT4, RNF12, and ERK1/2 protein levels were
ected with the indicated vectors, and REX1, RNF12, and ERK1/2 protein levels
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induced by LIF withdrawal, as evidenced by rapidly increased
expression of DNMT3B/Dnmt3b (Figures 1E and 1F), a factor
associated with lineage priming and differentiation, and Fgf5
(Figure 1F), an early marker of ESC priming toward the epiblast
lineage. These data indicate that RNF12/Rlim gene inactivation
promotes exit from the stem cell state toward a lineage-primed
state.
We then determined whether RNF12 E3 ligase activity is
required to maintain expression of stem cell-specific genes. To
this end, we transfected Rlim /y ESCs with either the wild-
type mouse RNF12 or an E3 ubiquitin ligase-defective mutant
of RNF12 (H569A/C572A). The NANOG/KLF4/DNMT3B gene
signature observed in Rlim /y ESCs (Figures 1E and 1F) is
rescued by expression of wild-type RNF12, but not RNF12
H569A/C572A (Figure 1G, left panel). In contrast, OCT4 levels
are unaffected by RNF12 E3 ligase activity (Figure 1G, left panel).
As expected, degradation of REX1, which is ubiquitylated by
RNF12 to initiate imprinted XCI (Gontan et al., 2012), requires
RNF12 catalytic activity (Figure 1G, right panel). RNF12 E3 ligase
activity is therefore required for maintenance of stem cell-spe-
cific genes to suppress differentiation. Mutational inactivation
of RNF12 thus alters the developmental potential of stem cells,
leading to abnormal neural marker induction and acquisition of
neuronal cell morphology.
Characterization of RNF12 Mutations Identified in XLID
Patients
Our data implicating RNF12 E3 ubiquitin ligase activity in stem
cell maintenance and neuronal differentiation suggest that
patient-derived XLID mutations may disrupt RNF12 catalytic
activity. P587R and R599C XLID mutants reside within the
RING domain of RNF12 that is responsible for E3 ubiquitin
ligase catalytic activity (Figure 2A) (Das et al., 2013; Hodson
et al., 2014; Joazeiro et al., 1999). Y356C and R387C lie in a
basic stretch reportedly involved in RNF12 substrate binding
(Figure 2A) (Gontan et al., 2012; Ostendorff et al., 2002). We
therefore sought to elucidate the effect of XLID-associated mu-
tations on RNF12.
To functionally characterize RNF12/RLIM XLID mutants, we
developed a strategy to replace endogenous RNF12 in ESCs.
When expressed in Rlim /y ESCs, human RNF12 and XLID
mutants are expressed at comparable levels (Figure 2B). XLID
mutations in other genes have been found to disrupt protein sta-
bility, exemplified by KDM5C (Brookes et al., 2015). However,Figure 2. RNF12 Protein Stability, Dimerization, and Nuclear Localizat
(A) Schematic of RNF12 indicating location of XLID mutations. NLS, nuclear loca
(red circles) within the RNF12 RING domain. Adapted from Metzger et al. (2014)
(B) Rlim /y ESCs were transfected with WT human RNF12 or XLID mutants, an
(C) Rlim /y ESCs were transfected with WT RNF12 or XLID mutants and treated
levels were determined by immunoblotting.
(D) Quantification of western blot signals shown in (C). Data are represented as m
(E)Rlim/y ESCswere transfectedwith indicated vectors and treatedwith 10 mM
(F) Rlim +/y or Rlim/y ESCs were transfected with the indicated constructs, and
by immunoblotting.
(G) ESCs treated as in (F) were fixed, and subcellular localization of WT RNF12 or X
(H)Rlim/y ESCswere transfectedwith N-terminal FLAG- or HA-taggedWTRNF
immunoblot analysis with FLAG or HA antibodies.
See also Figure S2.when expressed in Rlim /y ESCs treated with cycloheximide,
wild-type human RNF12 and RNF12 XLID mutant proteins
display a similar rate of degradation (Figures 2C and 2D), sug-
gesting that these mutations do not have a major impact on
RNF12 protein stability. Proteasomal inhibition stabilizes wild-
type RNF12 and XLID mutants to a similar extent (Figure 2E),
indicating that these proteins are turned over at a similar rate.
Our data therefore argue that RNF12 stability is unlikely to under-
pin pathogenesis of patient-derived RNF12 XLID mutants.
RNF12 XLID Mutants Localize to the Nucleus and
Dimerize
We next determined the effect of XLID point mutants on RNF12
regulation. RNF12 nuclear translocation is required for function
and is driven by phosphorylation of a nuclear localization signal
(NLS) (Figure 2A) motif by an unidentified kinase (Jiao et al.,
2013). RNF12 XLID mutants are phosphorylated at Ser212/
214 within this motif to a similar level as wild-type human
RNF12 (Figure 2F). We also examined sub-cellular localization
of RNF12 XLID mutants. Wild-type human RNF12 expressed
in Rlim /y ESCs localizes to the nucleus as expected (Fig-
ure 2G), similar to endogenous mouse RNF12 (Figure S2).
RNF12 XLID mutants also localize to the nucleus in a manner
similar to wild-type RNF12 (Figure 2G). Finally, because RING
E3 ligases frequently function as dimers (Metzger et al.,
2014), we addressed whether RNF12 XLID mutations disrupt
RNF12 dimerization. When expressed in Rlim /y ESCs,
FLAG-tagged wild-type RNF12 co-immunoprecipitates with
hemagglutinin (HA)-tagged wild-type RNF12 (Figure 2H), con-
firming that RNF12 dimerizes or self-associates in vivo.
RNF12 XLID mutants self-associate to a similar level as wild-
type RNF12 (Figure 2H), indicating that dimerization is not dis-
rupted by RNF12 XLID mutations. Altogether, our data show
that RNF12 XLID mutants are essentially indistinguishable
from wild-type RNF12 in terms of stability, regulation of subcel-
lular localization, and dimerization.
XLID Mutations Impair RNF12 Substrate Ubiquitylation
and Degradation In Vivo
These findings prompted us to investigate the impact of RNF12
XLID mutations on substrate processing. RNF12 controls
X-linked gene expression by ubiquitylating the REX1 transcrip-
tion factor to initiate imprinted XCI (Gontan et al., 2012), suggest-
ing that REX1 may be a relevant RNF12 target in ID. REX1ion Are Unaltered by XLID-Associated Mutations
lization signal; NES, nuclear export signal. Inset: positions of XLID mutations
.
d RNF12 and ERK1/2 levels were determined by immunoblotting.
with 350 mM cycloheximide (CHX) for the indicated times. RNF12 and ERK1/2
ean ± SEM (n = 3).
MG132 for 6 hr. RNF12 and ERK1/2 levels were determined by immunoblotting.
RNF12 NLS phosphorylation at Ser212/Ser214 and total RNF12 were analyzed
LIDmutants was analyzed via immunofluorescence and confocal microscopy.
12 or XLIDmutants and lysates subjected to FLAG co-immunoprecipitation and
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Figure 3. RNF12 XLID Mutations Disrupt
Substrate Processing In Vivo
(A) Rlim /y ESCs were transfected with HA-REX1
and WT RNF12 or XLID mutants. Ubiquitylated
proteins were captured using HALO-TUBE resin,
and HA-REX1 ubiquitylation was determined by
immunoblotting. Total ubiquitin levels are shown as
a control.
(B) Quantification of HA-REX1 ubiquitylation shown
in (A) was normalized to the HA-REX1 input signal.
(C) Rlim +/y or /y ESCs were transfected with
HA-REX1 and WT RNF12 or XLID mutants, and
HA-REX1 and ERK1/2 levels were determined by
immunoblotting.
(D) Quantification of HA-REX1 signal intensities
for RNF12 XLID mutants relative to WT RNF12
shown in (C).
(E) Rlim +/y or /y ESCs were transfected with the
indicated vectors, treated with 10 mM MG132 for
6 hr before RNF12 immunoprecipitation. REX1 and
RNF12 levels were determined by immunoblotting.
(F) Quantification of REX1 interaction with RNF12
XLID mutants relative to WT RNF12.
Data are represented as mean ± SEM (n = 3).
HA-REX1 ubiquitylation in (A) and degradation in (C)
were determined at 48 and 24 hr post-transfection,
respectively. See also Figure S3.ubiquitylation is essentially undetectable in Rlim /y ESCs (Fig-
ure 3A) but is induced by 48 hr expression of human RNF12, as
measured by specific capture of ubiquitylated HA-REX1 on a
tandem ubiquitin binding element (TUBE) (Figure 3A). We show
that HA-REX1 ubiquitylation and degradation depend on
RNF12 E3 ubiquitin ligase activity in these assays (Figure S3).
RNF12 XLID RING domain mutants also display significantly1604 Cell Reports 23, 1599–1611, May 8, 2018impaired REX1 ubiquitylation compared
to wild-type human RNF12 (Figures 3A
and 3B). However, XLID mutants in the
basic region retain the ability to promote
REX1 ubiquitylation (Figures 3A and 3B),
suggesting that a subset of RNF12 XLID
mutants disrupts substrate ubiquitylation
in vivo.
We then addressed whether RNF12
XLID mutants alter REX1 proteasomal
degradation. In Rlim /y ESCs, HA-REX1
protein is stabilized and highly expressed
when compared to Rlim +/y ESCs (Fig-
ure 3C). Expressing human RNF12 for
24 hr in Rlim /y ESCs restores REX1
degradation (Figure 3C). In contrast,
RNF12 P587R and R599C mutants in the
RING domain are significantly impaired
for REX1 degradation (Figures 3C and
3D), consistent with reduced REX1 ubiq-
uitylation (Figures 3A and 3B). RNF12
XLID mutants Y356C and R387C in the
basic region retain the ability to promote
REX1 ubiquitylation (Figures 3A and 3B)and degradation (Figures 3C and 3D). Altogether, our results
indicate that although all RNF12 XLID mutants retain some E3
ubiquitin ligase activity, a subset of mutations within the
RING domain significantly impair REX1 substrate ubiquitylation
and degradation. These data suggest that defective RNF12
substrate processing is a potential mechanism underpinning
XLID.
RNF12 XLID Mutants Display Impaired E3 Ubiquitin
Ligase Catalytic Activity
Our findings prompted us to investigate the mechanisms by
which XLID mutations affect RNF12-dependent ubiquitin trans-
fer. First, we examined whether RNF12 XLID mutants alter sub-
strate engagement, because both the RING domain and the
basic region mutated in XLID are reportedly involved in RNF12
substrate recruitment (Gontan et al., 2012; Ostendorff et al.,
2002). Following treatment with the proteasomal inhibitor
MG132, REX1 efficiently co-immunoprecipitates with wild-type
RNF12 (Figure 3E). RNF12 Y356C and R387C interact with
REX1 to a similar level as wild-type RNF12 (Figures 3E and 3F).
RNF12 RING domain mutants P587R and R599C show
enhanced REX1 substrate binding (Figures 3E and 3F), suggest-
ing that RNF12 RING domain mutants trap REX1 substrate in a
nonproductive complex. Substrate trapping by an RNF12
RING mutant has previously been described and exploited to
identify SMAD7 as an RNF12 substrate (Zhang et al., 2012).
These results indicate that although RNF12 XLID mutants
display impaired REX1 substrate ubiquitylation and degradation,
this is not explained by defective substrate engagement.
A subset of RNF12 XLID mutations that alter substrate modifi-
cation in vivo is found in the catalytic RING domain and therefore
may interfere with catalytic E3 ubiquitin ligase activity. We
sought to directly test this possibility in vitro. Because E3 ubiqui-
tin ligase activity can vary depending on the E2-conjugating
enzyme used (Christensen et al., 2007), we systematically deter-
mined the E2 or E2s that function with RNF12. A ubiquitin chain
elongation assay of recombinant RNF12, in combination with flu-
orescently labeled ubiquitin (Ub-IR800), UBE1 E1, and a panel of
31 E2 enzymes, identified UBE2D and UBE2E families and
UBE2W as major RNF12 partner E2-conjugating enzymes (Fig-
ure S4A). Of those, RNF12-UBE2D shows the highest chain-
elongating activity (Figure S4A).
We then sought to investigate whether RNF12 XLID mutants
alter substrate ubiquitylation by RNF12-E2 pairs in vitro. In the
first instance, we used REX1 as a model RNF12 substrate.
RNF12-UBE2D1 catalyzes efficient REX1 substrate ubiquityla-
tion, in addition to background ubiquitin chain elongation (Fig-
ures 4A and S4B). XLID mutants P587R and R599C in the
RING domain of RNF12 display severely compromised REX1
ubiquitylation (Figures 4A, 4B, and S4B), whereas RNF12 XLID
mutations Y356C and R387C in the basic region display reduced
but less severe defects in REX1 substrate ubiquitylation (Figures
4A, 4B, and S4B). Similar results are obtained with RNF12-
UBE2E2 or RNF12-UBE2W pairs (Figures 4A and 4B), although
RNF12-UBE2W primarily mono-ubiquitylates REX1 (Figure 4A).
Our data therefore demonstrate that XLID mutations interfere
with RNF12 E3 ubiquitin ligase activity, independent of the part-
ner E2.
An important question is whether RNF12 XLIDmutants disrupt
ubiquitylation of other RNF12 substrates. In addition to REX1,
RNF12 ubiquitylates the TGF-b/BMP pathway regulator
SMAD7 in ESCs (Zhang et al., 2012). We confirm that RNF12
directly ubiquitylates SMAD7 in vitro, and this activity is disrup-
ted by XLID mutations to a similar extent to that previously
observed for REX1 ubiquitylation (Figure 4C). These data indi-
cate that RNF12 XLIDmutations disrupt ubiquitylation ofmultiplesubstrates, strongly suggesting that effects of RNF12 XLID
mutations are unlikely to be substrate specific. Altogether, our
results demonstrate that XLID mutations in the catalytic RING
domain and the basic region disrupt RNF12 substrate ubiquityla-
tion, albeit with different potency.
RNF12 XLIDMutants Disrupt Ubiquitin Discharge from a
Partner E2-Conjugating Enzyme
Akey facet ofRINGE3 ligaseactivity is theability to catalyzeubiq-
uitin transfer from a ubiquitin-loaded E2-conjugating enzyme to
free lysine. Because these assays are substrate independent,
we investigated whether RNF12 XLID mutants interfere with E2
ubiquitin discharge. As expected,wild-typeRNF12drives ubiqui-
tin discharge fromubiquitin-loadedUBE2D1 (Figures 4D and 4E).
RNF12 XLID mutants in both the catalytic RING domain and the
basic region are impaired in their ability to promote E2 ubiquitin
discharge (Figures 4D and 4E). This is consistent with the key
role of the RING domain in ubiquitin transfer by an RNF12-E2
complex. However, these results also uncover a previously unap-
preciated role for the RNF12 basic region in promoting efficient
ubiquitin transfer from an E2-conjugating enzyme. Therefore,
XLIDpatient-derivedRNF12mutations disrupt E3ubiquitin ligase
catalytic activity by interfering with distinct functional regions.
RNF12 XLID Knockin ESCs Confirm Defects in RNF12
Substrate Degradation, Stem Cell Maintenance, and
Neural Differentiation
We next sought to directly address the impact of endogenous
RNF12/Rlim XLID mutation on RNF12 substrate processing
and stem cell differentiation using a CRISPR/Cas9 knockin strat-
egy.We generated paired controlRlimwild-type knockin (WT-KI)
and Rlim R575C (the mouse equivalent of the human RNF12
R599C XLIDmutation) knockin (R575C-KI) ESC lines (Figure S5).
Rlim R575C/y ESCs display increased REX1 substrate expres-
sion when compared to Rlim WT-KI ESCs (Figure 5A). This is
caused by reduced REX1 ubiquitylation and degradation,
because REX1 displays increased half-life in Rlim R575C/y
ESCs (0.61 ± 0.08 hr) when compared to Rlim WT-KI ESCs
(0.38 ± 0.05 hr) (Figure 5B). The effect of RNF12 XLID knockin
(Rlim R575C/y) is less dramatic than that of gene knockout
(Rlim /y) (Figures 5A and 5B), likely as a result of noncatalytic
functions of RNF12 in REX1 processing (Wang et al., 2017). How-
ever, these data demonstrate that XLID mutation of the endoge-
nous RNF12/Rlim gene locus disrupts substrate degradation.
Finally, we explored functional effects of RNF12 XLIDmutation
on ESCmaintenance and neural differentiation. When cultured in
the absence of LIF,RlimR575C/y ESCs display reducedNANOG
and increased DNMT3B expression compared to Rlim WT-KI
ESCs (Figure 5C). We thus tested induction of neural lineage
markers following ESC differentiation in N2B27 media. When
compared to Rlim WT-KI ESCs, Rlim R575C/y ESCs display
increased expression of neural markers Sox1 and Pax6 at early
time points (Figure 5D). These data indicate that RNF12 XLID
mutation accelerates ESC neural differentiation, echoing our
previous observations (Figure 1). As observed previously, the
RNF12 XLID knockin (Rlim R575C/y) mutation phenotype is
less dramatic than RNF12/Rlim gene knockout. Nevertheless,
our results confirm that RNF12 mutations found in XLID patientsCell Reports 23, 1599–1611, May 8, 2018 1605
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Figure 4. RNF12 XLID Mutants Display Impaired E3 Ubiquitin Ligase Catalytic Activity
(A) In vitro REX1 substrate ubiquitylation assay of WT RNF12 and XLID mutant proteins using UBE2D1, UBE2E2, and UBE2W E2-conjugating enzymes. Fluo-
rescently labeled ubiquitylated proteins were detected by infrared scan (Ub-IR800), and REX1 and RNF12 levels were determined by immunoblotting. Specific
ubiquitylated REX1 (REX1-Ubn) and RNF12 (RNF12-Ubn) signals are indicated. *Nonspecific fluorescent band.
(B) Quantification of REX1 ubiquitylation shown in (A).
(C) In vitro REX1 and SMAD7 ubiquitylation assays performed as in (A) (Ub-IR800, top panel). REX1 and SMAD7 levels were determined by Coomassie staining
(bottom panel). *Nonspecific band.
(D) RNF12 XLID mutant proteins are impaired for UBE2D1 E2 ubiquitin discharge. Coomassie-stained gels showing RNF12-mediated ubiquitin (Ub) discharge
from pre-formed UBE2D1 conjugates (UBE2D1-Ub). *Nonspecific band. RNF12 levels were determined by immunoblotting.
(E) Determination of E2 discharge reaction rate from signal intensities obtained in (D).
Data are represented as mean ± SEM (n = 3). See also Figure S4.
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Figure 5. CRISPR/Cas9 Knockin RNF12 XLID Mutant ESCs Display Defects in Substrate Degradation and Abnormal Differentiation
(A) Rlim WT and XLID knockin ESCs (WT-KI and R575C-KI) (see Figure S5 for details) were analyzed for REX1, RNF12, and ERK1/2 levels by immunoblotting.
(B) Rlim +/y (green line), Rlim /y, RlimWT-KI, and Rlim R575C-KI ESCs were transfected with HA-REX1 and treated with 350 mM cycloheximide (CHX) for the
indicated times. HA-REX1 and ERK1/2 levels were determined by immunoblotting (top panel). Quantification of HA-REX1 signal intensities determined in (B) was
used to calculate HA-REX1 protein half-life (h) in the indicated ESC lines.
(C) Rlim WT-KI and Rlim R575C-KI ESCs were cultured in absence of LIF, and NANOG, DNMT3B, and ERK1/2 levels were determined by immunoblotting.
(D) Rlim WT-KI and Rlim R575C-KI ESCs were cultured in N2B27 media for the indicated times, and Sox1 and Pax6 mRNA expression was determined by
qRT-PCR. Data are represented as mean ± SD (n = 3).
*Nonspecific band. See also Figure S5.disrupt substrate ubiquitylation, driving aberrant stem cell differ-
entiation and neuronal specification.
DISCUSSION
In this paper, we show that RNF12/RLIM XLID mutations disrupt
RNF12 E3 ligase activity and that RNF12 catalytic function regu-
lates differentiation of stem cells to neural cells. Our data provide
a framework to understand how RNF12/RLIM mutations cause
XLID and shed light on potential mechanisms that regulate
development of the nervous system. Our findings also provide
further evidence of the importance of PTMs such as the protein
ubiquitylation system in ID.
In this regard, we elucidate biochemical mechanisms bywhich
XLID mutations disrupt protein ubiquitylation by RNF12. We
show that XLID mutations impair RNF12 ubiquitin transfer byinterfering with distinct functional regions. RING domainmutants
markedly diminish RNF12 E3 ligase activity both in vitro and in
cells, while mutation of a previously unappreciated accessory
basic region of RNF12 also disrupts catalysis. However,
RNF12 basic region mutations are less potent and were uncov-
ered only by highly sensitive initial rate measurement of RNF12
substrate ubiquitylation and E2 ubiquitin discharge in vitro.
This facet of the RNF12 catalytic mechanism is reminiscent of
the CBL-B RING E3 ubiquitin ligase, which uses a non-RING
priming element to ensure optimized ubiquitin transfer (Dou
et al., 2013). However, detailed structural studies are required
to fully characterize the role of the RNF12 basic region in
catalysis.
A key question concerns the mechanism by which RNF12
basic region mutations cause XLID. Although our biochemical
data demonstrate that RNF12 XLID mutants are significantlyCell Reports 23, 1599–1611, May 8, 2018 1607
impaired for E3 ubiquitin ligase activity independent of E2 or
substrate, we observe significant REX1 substrate processing
by RNF12 XLID mutants in vivo. This discrepancy could be ex-
plained by observations showing RNF12 also promotes REX1
degradation via alternative mechanisms, e.g., recruiting other
E3 ligases (Wang et al., 2017). RNF12 XLID mutants may there-
fore lack E3 ligase activity while retaining other properties
required for REX1 regulation. Whether RNF12 XLID mutants
affect processing of substrates that function in neural develop-
ment is not known. However, we observe impaired RNF12 E3
ligase activity toward at least two RNF12 substrates, which in-
dicates that RNF12 XLID mutations are likely to affect RNF12
substrate processing in a variety of developmental contexts.
Furthermore, mutations that subtly alter biochemical function,
such as RNF12 XLID mutations in the basic region, may, over
the timescale of nervous system development, have a cumula-
tive impact leading to XLID. In support of this notion, very weak
activating mutations in genes encoding components of the
RAS-ERK1/2 mitogen-activated protein kinase (MAPK)
signaling pathway can cause the developmental disorder
known as Noonan syndrome (Roberts et al., 2007; Tartaglia
et al., 2007).
Finally, we employ a stem cell model system to show that
RNF12/Rlim gene disruption and introduction of an XLID muta-
tion in male ESCs affect stem cell maintenance and kinetics of
neural development. This phenotype has been described in
other models of ID (Telias and Ben-Yosef, 2014; Telias et al.,
2013), thereby implicating deregulated neural development, dif-
ferentiation, and function as potentially important pathogenic
mechanisms in XLID. We provide evidence that deregulated
stem cell maintenance and specification of neural progenitors
are observed by RNF12/Rlim deletion or XLID mutation. Further
investigation into the function of RNF12 in regulating the stem
cell state is required to fully understand its role in XLID. In this re-
gard, the stem cell-specific factor NANOG controls RNF12
mRNA expression (Navarro et al., 2011), while paradoxically,
our data show that RNF12 promotes NANOG expression. This
tight cross-regulation may be important to prevent XCI in plurip-
otent cells while promoting ESC differentiation once RNF12
expression is extinguished following XCI. This system would
thereby ensure that XCI is closely coupled to the onset of differ-
entiation. Future research will also seek to address how RNF12/
Rlim mutations affect mammalian neural development and
explore the molecular functions of RNF12 in development of
the nervous system by identifying RNF12 substrates whose
ubiquitylation is required for correct neural specification and
neuronal function.EXPERIMENTAL PROCEDURES
Cell Culture
WT male mouse ESCs (CGR8 line) were cultured in 0.1% gelatin (w/v)-coated
plates in DMEM containing 10% FCS (v/v), 5% knockout serum replacement
(v/v), 2 mM glutamine, 0.1 mM minimum essential media (MEM) nonessential
amino acids, 1 mM sodium pyruvate, and penicillin and streptomycin (all from
Thermo Fisher Scientific); 0.1 mM b-mercaptoethanol (Sigma-Aldrich); and
100 ng/mL LIF in a controlled atmosphere at 5% CO2 and 37
C. After 24 hr,
transfected cells were selected with 2 mg/mL puromycin and grown for further
24 hr. For differentiation assays, cells were cultured in absence of LIF for up to1608 Cell Reports 23, 1599–1611, May 8, 20184 days. For neural differentiation assays, cells were cultured in N2B27 media
composed of 1% B27 supplement (v/v), 0.5% N2 supplement (v/v), and
2mMglutamine (all from Thermo Fisher Scientific); 0.1mM b-mercaptoethanol
(Sigma-Aldrich); and penicillin and streptomycin in 1:1 DMEM/F12:Neurobasal
medium (both from Thermo Fisher Scientific). The media was changed every
48 hr. For protein synthesis or proteasome inhibition, cells were treated with
350 mM cycloheximide or 10 mM MG132 (both from Sigma-Aldrich),
respectively.
Transfection and Plasmids
ESCs were transfected with Lipofectamine LTX (Thermo Fisher Scientific) ac-
cording to the manufacturer’s instructions. Plasmids used in this study gener-
ated by the Division of Signal Transduction and Therapy, University of Dundee,
in pCAGGS puro backbone were mouse RNF12 (DU50610), RNF12 H569A
C572A (DU50631), and HA-REX1 (DU58024); human RNF12 (DU53765),
RNF12 Y356C (DU53771), RNF12 R387C (DU53772), RNF12 P587R
(DU53776), and RNF12 R599C (DU53773); human 3FLAG RNF12
(DU53879), RNF12 Y356C (DU53880), RNF12 R387C (DU53881), RNF12
P587R (DU53882), and RNF12 R599C (DU53883); and human HA
RNF12 (DU53884), RNF12 Y356C (DU53885), RNF12 R387C (DU53886),
RNF12 P587R (DU53887), and RNF12 R599C (DU53888). Plasmids generated
in pGEX6P1 backbone for expression in BL21 E. coli were human RNF12
(DU53876), RNF12 R387C (DU53877), RNF12 P587R (DU53878), RNF12
Y356C (DU53897), and RNF12 R599C (DU53898) and mouse REX1
(DU53244). All cDNA clones can be found at the Medical Research Council
Protein Phosphorylation and Ubiquitin Unit (MRC-PPU) Reagents and Ser-
vices website http://mrcppureagents.dundee.ac.uk/.
CRISPR/Cas9 D10A Genome Editing
For generation of Rlim /y ESCs, we transfected WT ESCs with pX335 and
pKN7 vectors (Addgene) containing the guide RNA (gRNA) sequences target-
ing Rlim exon 5 (sense: 50-gAT AAA TGT TAA CCG TAA CAA TGG-30, anti-
sense: 50-gAA TCT GAA ATC ACC GCT GTT TGG-30). Transfected cells
were selected with 3 mg/mL puromycin for 48 hr and then plated at clonal
density. Clones were analyzed by western blot and genomic DNA
sequencing to confirm RNF12 knockout (Figure S1). To generate Rlim WT-in-
ternal ribosome entry site (IRES)-GFP (Rlim wt/y) and R575C-IRES-GFP (Rlim
R575C/y) knockin ESCs cells, WT ESCs were transfected with vectors
encoding guide RNAs targeting exon 5 in the Rlim gene (pBABED Puro U6
and pX335 containing 50-GCA GGG CAG TCT TAT CTT CT-30 and 50-GTG
GAA TTC TCA GAC AAC CAG-30 sequences, respectively) and a donor vec-
tor containing RNF12 amino acids 84 to 600 followed by an IRES and EGFP.
Transfected cells were selected as earlier and subjected to single-cell sort-
ing. Single EGFP-positive cells were expanded and screened for EGFP
expression via western blot, and knockin mutation was confirmed by
genomic DNA sequencing.
Western Blotting
Cells were harvested in lysis buffer containing 20 mM Tris (pH 7.4),
150 mM NaCl, 1 mM EDTA, 1% Nonidet P-40 (NP-40) (v/v), 0.5% sodium de-
oxycholate (w/v), 10 mM b-glycerophosphate, 10 mM sodium pyrophosphate,
1 mM NaF, 2 mM Na3VO4, and Roche Complete Protease Inhibitor Cocktail
Tablets. 10–30 mg of cell lysate was loaded in SDS-PAGE gels and transferred
to polyvinylidene fluoride (PVDF) membranes. Membranes were blocked
with Tris buffered saline-tween 20 (TBS-T) 5% nonfat milk buffer (w/v). Primary
antibodies used were RNF12 (Novus Biologicals), ERK1/2 (Santa Cruz
Biotechnology), HA tag and REX1 (Abcam), ubiquitin (Dako), NANOG
(ReproCELL), KLF4 (R&D Systems), DNMT3B (Imgenex), OCT3/4 (Santa
Cruz Biotechnology), and FLAG (Sigma-Aldrich), all at 1:1,000. The following
antibodies were raised in sheep by the Division of Signal Transduction Ther-
apy, University of Dundee: RNF12 (S691D, third bleed, raised against residues
1–271 of mouse RNF12, DU49042) and RNF12 pSer212/214 (SA310, second
bleed, raised against a QRRARpSRpSPEHRR phosphopeptide, where pS is
phospho-serine). Both were used at 1 mg/mL after secondary antibody incuba-
tion, and membranes were subjected to chemiluminescence detection with
Immobilon Western Chemiluminescent HRP (horseradish peroxidase) Sub-
strate (Millipore) using a Gel-Doc XR+ System (Bio-Rad).
Immunoprecipitation
20 mL of protein G agarose beads was washed three times with lysis buffer and
incubated with 1 mg of mouse embryonic stem cell (mESC) lysate and 2 mg of
antibody for 16–20 hr at 4C. Beads were then washed three times with
500 mM lysis buffer, and immunoprecipitates were eluted with SDS sample
buffer and boiled for 5 min for further analysis.
Immunofluorescence
Cells were seeded in gelatin-coated coverslips and fixed with PBS 4% para-
formaldehyde (PFA) (w/v). Fixed cells were permeabilized in PBS 0.5% Triton
X-100 (v/v) for 5 min at room temperature (RT), blocked with PBS 3% BSA
(w/v), and incubated with TUJ1 (Tubulin b 3, BioLegend) at 1:500, RNF12 anti-
body (S691D, third bleed, Division of Signal Transduction and Therapy, Univer-
sity of Dundee) at 1:200, or RNF12 antibody (Novus Biologicals) at 1:200 in
blocking buffer for 2 hr at RT. Donkey anti-mouse Alexa 555, donkey anti-
sheep Alexa 488, or donkey anti-mouse Alexa 488 (Thermo Fisher Scientific)
were used as secondary antibodies at 1:500. Actin red 555 reagent (Thermo
Fisher Scientific) was used for actin staining, and Hoechst (Sigma-Aldrich) at
1:10,000 was used for DNA staining. Cells were mounted using Fluorsave re-
agent (Millipore). Images were acquired in a Zeiss 710 confocal microscope
and processed using ImageJ (NIH) and Photoshop CS5.1 software (Adobe).
Neurite outgrowth was estimated by average outgrowth per cell, calculated
as the ratio between neurite outgrowth length and total nuclei number, and
quantified using the NeuriteTracer (Pool et al., 2008) and Cell Counter plugins
in ImageJ (NIH). TUJ1(+) signal area per cell was determined as the ratio be-
tween the TUJ1(+) area and the Hoechst(+) area and quantified using the mea-
surements tool in Volocity (PerkinElmer).
In Vitro Ubiquitylation Assays
DyLight 800 maleimide (Thermo Fisher Scientific) Ub-IR800 was generated as
described (Kumar et al., 2015). For ubiquitylation reactions, 1.5 mg of REX1
or SMAD7 were incubated with a 20 mL mix containing 0.1 mM UBE1,
0.05 mM E2 (UBE2D1, UBE2E2, UBE2W, or 28 other E2s tested), and
140 nMRNF12 (all from the Division of Signal Transduction Therapy, University
of Dundee); 2 mM Ub-IR800; 0.5 mM Tris(2-carboxyethyl)phosphine (TCEP)
(pH 7.5), and 5 mM ATP (both from Sigma-Aldrich); 50 mM Tris-HCl (pH 7.5);
and 5mMMgCl2 for 30min at 30
C. Reactions were stopped with SDS sample
buffer and boiled for 5 min. Samples were loaded in 4%–12%Bis-Tris gradient
gels (Thermo Fisher Scientific). Gels were then scanned using an Odyssey CLx
Infrared Imaging System (LI-COR Biosciences) for detection of fluorescently
labeled ubiquitylated proteins. After scanning, proteins were transferred to
PVDF membranes and analyzed via western blot.
Cell-Based Ubiquitylation Assays
Modified haloalkane dehalogenase (HALO)-tagged tandem ubiquitin binding
element (HALO-TUBE) beads were produced as described (Emmerich et al.,
2013). For REX1 ubiquitylation assays, mESCs were transfected with REX1
and RNF12 expression vectors and cultured for 48 hr. Cells were extracted
in lysis buffer supplemented with 100 mM iodoacetamide (Sigma-Aldrich)
and 2 mg of protein were incubated with 20 mL of HALO-TUBE beads for
4 hr at 4C. Beads were then washed with 500 Mm NaCl lysis buffer, eluted
with SDS sample buffer, and boiled for 5 min. The presence of ubiquitylated
proteins was analyzed via western blot.
E2 Discharge Assays
UBE2D1 discharge assays were performed as described (Plechanovova´ et al.,
2012). UBE2D1-ubiquitin thioester was prepared by incubating 100 mM
UBE2D1 with 0.2 mM UBE1 (Division of Signal Transduction Therapy, Univer-
sity of Dundee), 100 mM ubiquitin (Sigma), 3 mM ATP and 0.5 mM TCEP
(pH 7.5) (both from Sigma-Aldrich), 5 mM MgCl2, 50 mM Tris (pH 7.5), and
150 mM NaCl for 20 min at 37C. Reaction was stopped by depleting ATP
with 4.5 U/mL apyrase (New England Biolabs) for 10 min at RT. Then, 40 mM
UBE2D1-ubiquitin was incubated with 280 nM RNF12 and 150 mM L-lysine
in a buffer containing 50 mM Tris (pH 7.5), 150 mM NaCl, 0.5 mM TCEP, and
0.1% (v/v) NP-40 at RT. Reactions were stopped with nonreducing SDS
loading buffer and analyzed via SDS-PAGE. Gels were stained with Coomas-
sie staining (InstantBlue reagent, Expedeon) and scanned in an Odyssey CLxInfrared Imaging System (LI-COR Biosciences), and the protein signal was
quantified using Image Studio software (LI-COR Biosciences). Reaction rates
were determined by extrapolating protein signals in a standard curve of known
concentrations of UBE2D1-ubiquitin conjugate and plotting concentration
over time.
RNA Extraction and qPCR
Total RNA extraction was performed by a column-based system (Omega) and
then subjected to reverse transcription using iScript reverse transcriptase
(Bio-Rad) according to the manufacturer’s guidelines. qPCR reactions were
carried out using SsoFast EvaGreen Supermix (Bio-Rad) in a CFX384 real-
time PCR system (Bio-Rad). The DDCt method was used to express the rela-
tive RNA levels in the samples, and GAPDH expression was analyzed as a
loading control. Data were analyzed in Excel software (Microsoft) and
plotted in GraphPad Prism v.6.00 software (GraphPad). Primers used are listed
in Table S1.
Data Analysis
Pooled data are presented as mean ± SEM of at least three biological repli-
cates unless stated in the figure legend. Statistical significance was deter-
mined using ANOVA followed by Tukey’s post hoc test or Student’s t test,
and significant differences were considered when p < 0.05. For western blots,
densitometric analysis was performed using Image Lab software (Bio-Rad).
HA-REX1 half-life was determined by adjusting data to a one-phase decay
nonlinear fit in GraphPad Prism.
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